NovaGo Therapeutics

NovaGo Therapeutics is a Swiss clinical-stage biotechnology company focused on developing human antibody treatments that promote nerve growth and regeneration in the central nervous system. Its work addresses spinal cord injury, a condition that can disrupt nerve pathways and cause loss of sensation and movement, including paraplegia or tetraplegia. Because the central nervous system has limited capacity to repair nerve damage, functional recovery can be difficult.

NovaGo’s approach is to block Nogo-A, a protein that inhibits nerve-fiber growth, with therapeutic antibody candidates intended to support nerve repair and recovery of function. The company reports that its candidates have enhanced nerve repair and functional recovery in preclinical models. Its lead candidate, NG004, is being evaluated in a Phase 1b clinical trial for acute spinal cord injury. NovaGo’s stated aim is to help restore sensation and movement by encouraging regeneration where the central nervous system does not readily repair itself. The company is based in Schlieren, Switzerland, and shares information about its science, development pipeline, patient resources and company news.